All Articles

Merck’s investigational antibody–drug conjugate that targets receptor tyrosine kinase–like orphan receptor 1 (ROR1), zilovertamab vedotin, used in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) achieved a 100% (n=15) complete response (CR) rate, according to results presented at the 66th ASH Annual Meeting and Exposition, in San Diego, CA, and simultaneously published in Blood. Read More ›

Using cannabis to reduce pain associated with their cancer would be “highly” accepted among patients with multiple myeloma (MM), but more education is needed for oncology providers in discussing its use with these patients, according to results of a survey presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA Read More ›

The financial burden often accompanying a cancer diagnosis, coupled with consequent unmet health-related social needs like food insecurity (FI), may be associated with increased trips to the emergency department (ED). Ongoing screening of these patients to help identify areas to intervene and, perhaps, reduce these trips is warranted. Read More ›

The first responders who were exposed to high levels of airborne dust, gases, and potential cancer-causing substances at Ground Zero following the 9/11 attacks that destroyed the Twin Towers in New York may now be facing an increased risk of developing leukemia and exhibit a distinct spectrum of precancerous genetic changes, according to data presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Read More ›

Officials with the FDA have approved durvalumab (Imfinzi; AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Read More ›

Zenocutuzumab-zbco (Bizengri; Merus) has been granted accelerated approval for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy or advanced, unresectable, or metastatic non–small cell lung cancer harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. Read More ›

On November 20, 2024, officials with the FDA granted accelerated approval to zanidatamab-hrii (Ziihera; Jazz Pharmaceuticals, Inc), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test. Read More ›

On November 19, 2024, the FDA approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection; Sandoz) under Project Renewal, a public health initiative under the Oncology Center of Excellence program, which is designed to update labeling information for certain older oncology drugs to ensure information is clinically meaningful. Read More ›

On December 13, 2024, FDA officials approved cosibelimab-ipdl (Unloxcyt; Checkpoint Therapeutics, Inc), a programmed death ligand-1 (PD-L1)-blocking antibody, for adults with locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation or metastatic cutaneous squamous cell carcinoma. Read More ›